Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

The significance of cyclin D1 expression in plasma cell myeloma was examined by immunohistochemical analysis using a newly available rabbit monoclonal antibody with superior staining properties. Two patterns of positive staining were observed, each associated with distinct pathologic features. Strong cyclin D1 staining was associated with increased plasma cells at diagnosis (P=.026), lymphoplasmacytic morphologic features (P=.029), CD20 expression (P=.040), and t(11;14)(q13;q32) as detected by interphase fluorescence in situ hybridization with simultaneous CD138 immunofluorescence (P<.001). In contrast, weak staining was associated with hyperdiploidy (P=.02) and gains of the CCND1 locus (P=.01). Overall survival was longer in the cyclin D1+ cases than in cyclin D1- cases (estimated 3-year survival, 73% vs 27%; P=.005). Improved survival was seen in the strongly positive and weakly positive groups compared with cyclin D1- cases (P=.005). This report shows for the first time that cyclin D1 immunohistochemical analysis can provide prognostic information in plasma cell myeloma.

[1]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[2]  Raju Tomer,et al.  Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. , 2004, Blood.

[3]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[4]  J. Chan,et al.  Consistent Immunostaining for Cyclin D1 Can Be Achieved on a Routine Basis Using a Newly Available Rabbit Monoclonal Antibody , 2004, The American journal of surgical pathology.

[5]  D. Reece,et al.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.

[6]  R. Bataille,et al.  Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report , 2004 .

[7]  O. Markovic,et al.  Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma , 2004, Medical oncology.

[8]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[9]  P. Moreau,et al.  t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma , 2003, Leukemia.

[10]  M. Baccarani,et al.  Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. , 2003, Blood.

[11]  P. Bergsagel,et al.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.

[12]  R. Bataille,et al.  CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. , 2003, Blood.

[13]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[14]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[15]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[16]  R. Fonseca,et al.  Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. , 2002, Blood.

[17]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[18]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[19]  C. Papadimitriou,et al.  Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens. , 2001, American journal of clinical pathology.

[20]  P. L. Bergsagel,et al.  Chromosome translocations in multiple myeloma , 2001, Oncogene.

[21]  R. Fonseca,et al.  The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. , 2000, American journal of clinical pathology.

[22]  M. Rocchi,et al.  Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). , 2000, The American journal of pathology.

[23]  R. Lamerz,et al.  Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance , 2000, British journal of haematology.

[24]  H. Avet-Loiseau,et al.  Cyclin D1 expression in patients with multiple myeloma. , 2000, The hematology journal : the official journal of the European Haematology Association.

[25]  M. Vasef,et al.  Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[26]  T. Facon,et al.  MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL , 1996, British journal of haematology.

[27]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[28]  R. Bartl,et al.  Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. , 1987, American journal of clinical pathology.

[29]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .

[30]  R. Alexanian.  Plasma cell neoplasms , 1978, CA: a cancer journal for clinicians.

[31]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.